The ALCYONE study randomized 706 newly diagnosed MM patients, ineligible for autologous transplantation, to receive standard therapy, i.e., nine cycles of PVD (pomalidomide, bortezomib, dexamethasone) or nine cycles of PVD plus the anti-CD38 monoclonal antibody daratumumab followed by maintenance therapy up to progression with daratumumab alone. The gene discussed is CD38; the disease is Miyoshi myopathy.